The GSK3B Knockout A-549 Polyclonal Cells product comprises a CRISPR/Cas9-mediated gene-disrupted population of A-549 cells with heterogeneous GSK3B editing. This polyclonal pool circumvents clonal selection artifacts and maintains natural signaling variability, offering a robust loss-of-function system for studying GSK3B in a lung adenocarcinoma context.
The parental A-549 cell line is a well-characterized model of human alveolar type II pneumocytes derived from a lung adenocarcinoma. These adherent epithelial cells are extensively employed in non-small cell lung cancer (NSCLC) research, enabling studies of oncogenic signaling, epithelial-mesenchymal transition, and drug sensitivity in a physiologically relevant pulmonary milieu.
GSK3B encodes glycogen synthase kinase-3 beta, a constitutively active serine/threonine kinase that phosphorylates glycogen synthase and beta-catenin, thereby inhibiting glycogen synthesis and promoting beta-catenin degradation. Growth factors and insulin trigger AKT-mediated phosphorylation of Ser9, which inactivates GSK3B and relieves repression of Wnt target genes such as CCND1 and MYC. GSK3B resides within the Axin?CAPC destruction complex and interacts with Dishevelled, FRAT1/2, and Protein Phosphatase 1. Additional upstream regulators include PKA, PKC, and p38 MAPK, while downstream effectors encompass c-Myc, Cyclin D1, NFAT, Snail, and pro-apoptotic factors like Bax. This kinase sits at the nexus of Wnt, PI3K-Akt, insulin, Hedgehog, and NF-kappaB pathways, coordinating cellular metabolism, proliferation, differentiation, and survival.
Disrupting GSK3B in A-549 adenocarcinoma cells provides a powerful tool to dissect its dual roles: acting as a tumor suppressor through beta-catenin degradation while potentially supporting proliferation via other substrates. The model allows examination of pathway crosstalk between Wnt, Akt, and Hedgehog cascades, all of which are commonly deregulated in NSCLC. It is particularly valuable for investigating how loss of GSK3B influences EMT, apoptotic thresholds, and metabolic reprogramming in the context of lung adenocarcinoma.
Researchers can employ these cells in western blotting for total and phospho-Ser9 GSK3B, RT-qPCR for CCND1/MYC, and beta-catenin/Tcf reporter assays to quantify Wnt pathway output. Co-immunoprecipitation enables detection of Axin?CGSK3B complexes, while functional assays??including migration, invasion, viability, apoptosis, and glycogen synthesis measurements??link GSK3B loss to phenotypic outcomes. Applications span mechanistic studies of Wnt-driven oncogenesis, high-throughput screening of GSK3 inhibitors for cancer or diabetes, and exploration of EMT in NSCLC. For further details, please contact Ascent Research.
